Keith Tapper
Stock Analyst at BMO Capital
(1.43)
# 2,501
Out of 4,479 analysts
3
Total ratings
100%
Success rate
3.2%
Average return
Main Sectors:
Top Industries:
3 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSHA Taysha Gene Therapies | Initiates: Outperform | $5 | $2.16 | +131.48% | 1 | Jun 27, 2024 | |
| ACAD ACADIA Pharmaceuticals | Initiates: Outperform | $31 | $15.84 | +95.71% | 1 | Jun 27, 2024 | |
| NGNE Neurogene | Initiates: Outperform | $65 | $38.46 | +69.01% | 1 | Jun 27, 2024 |
Taysha Gene Therapies
Jun 27, 2024
Initiates: Outperform
Price Target: $5
Current: $2.16
Upside: +131.48%
ACADIA Pharmaceuticals
Jun 27, 2024
Initiates: Outperform
Price Target: $31
Current: $15.84
Upside: +95.71%
Neurogene
Jun 27, 2024
Initiates: Outperform
Price Target: $65
Current: $38.46
Upside: +69.01%